A metabolite-derived analog of melanotan II, refined for MC4R preference and stripped of the C-terminal amide. It acts centrally rather than vascularly — unlike PDE5 inhibitors, which act on peripheral blood flow, bremelanotide modulates MC4R signalling in hypothalamic pathways governing sexual desire.
Completed a full development programme. The RECONNECT phase 3 trials supported approval for hypoactive sexual desire disorder in premenopausal women. An earlier intranasal formulation was abandoned after blood-pressure signals; the subcutaneous route was carried forward.
FDA-approved as Vyleesi for acquired, generalised hypoactive sexual desire disorder in premenopausal women. Prescription-only. Approval is narrow — it does not extend to men or to general sexual-performance use.
Nausea is common and frequently treatment-limiting. Transient blood-pressure increase and heart-rate decrease; contraindicated in uncontrolled hypertension or known cardiovascular disease. Focal hyperpigmentation with repeated use.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.